MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG, LLP, as the Company’s auditors for the current fiscal year. Shareho
Phase 1b dose established at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneExpansion study will evaluate TH1902 in solid tumors with high expression of Sortilin receptor MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-huma
We feel now is a pretty good time to analyse Theratechnologies Inc.'s ( TSE:TH ) business as it appears the company may...